Home LiteratureArticle Details
PMID: 16720975 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Antibody polyspecificity and neutralization of HIV-1: a hypothesis.

Human antibodies ·Vol. 14 ·No. 3-4 ·2005-00-00 ·Pages 59-67

Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM

Abstract

HIV-1 has evolved many ways to evade protective host immune responses, thus creating a number of problems for HIV vaccine developers. In particular, durable, broadly specific neutralizing antibodies to HIV-1 have proved difficult to induce with current HIV-1 vaccine candidates. The recent observation that some broadly neutralizing anti-HIV-1 envelope monoclonal antibodies have polyspecific reactivities to host antigens have raised the hypothesis that one reason antibodies against some of the conserved HIV-1 envelope trimer neutralizing epitopes are not routinely made may be down-regulation of some specificities of anti-HIV-1 antibody producing B cells by host B cell tolerance mechanisms.

MeSH Terms
AIDS Vaccines/immunology Antibodies, Monoclonal/immunology Antibody Specificity B-Lymphocytes/immunology HIV Antibodies/immunology HIV Antigens/immunology HIV-1/immunology Humans Neutralization Tests/methods
Chemicals
AIDS Vaccines Antibodies, Monoclonal HIV Antibodies HIV Antigens
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Haynes Barton F
Duke Human Vaccine Institute, Duke University School of Medicine, Durham NC 27710, USA. hayne002@mc.duke.edu
Moody M Anthony
Verkoczy Laurent
Kelsoe Garnett
Alam S Munir
References (69)
69 references, click to expand
  1. Rheumatologic manifestations of infection with human immunodeficiency virus (HIV).
    Ann Intern Med. 1989 Jul 15;111(2):158-67 PMID: 2662849
  2. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow.
    J Exp Med. 1991 May 1;173(5):1213-25 PMID: 1827140
  3. Intraclonal generation of antibody mutants in germinal centres.
    Nature. 1991 Dec 5;354(6352):389-92 PMID: 1956400
  4. The development and repertoire of B-1 cells (CD5 B cells).
    Immunol Today. 1991 Nov;12(11):389-91 PMID: 1723875
  5. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor.
    J Immunol. 1992 Jun 15;148(12):3885-91 PMID: 1602135
  6. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. II. A common clonal origin for periarteriolar lymphoid sheath-associated foci and germinal centers.
    J Exp Med. 1992 Sep 1;176(3):679-87 PMID: 1512536
  7. Peripheral B cell maturation. I. Immature peripheral B cells in adults are heat-stable antigenhi and exhibit unique signaling characteristics.
    J Immunol. 1992 Oct 15;149(8):2533-40 PMID: 1383316
  8. Receptor editing in self-reactive bone marrow B cells.
    J Exp Med. 1993 Apr 1;177(4):1009-20 PMID: 8459201
  9. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41.
    Immunity. 2005 Feb;22(2):163-73 PMID: 15723805
  10. Identification and characterization of circulating human transitional B cells.
    Blood. 2005 Jun 1;105(11):4390-8 PMID: 15701725
  11. Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow.
    J Exp Med. 2005 Jun 6;201(11):1771-80 PMID: 15939792
  12. B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88.
    J Immunol. 2005 Jun 15;174(12):7912-9 PMID: 15944297
  13. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.
    Science. 2005 Jun 24;308(5730):1906-8 PMID: 15860590
  14. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.
    Nature. 2002 Dec 12;420(6916):678-82 PMID: 12478295
  15. Antibody neutralization and escape by HIV-1.
    Nature. 2003 Mar 20;422(6929):307-12 PMID: 12646921
  16. Rapid evolution of the neutralizing antibody response to HIV type 1 infection.
    Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9 PMID: 12644702
  17. Hypermutation in human B cells in vivo and in vitro.
    Ann N Y Acad Sci. 2003 Apr;987:158-65 PMID: 12727635
  18. Systemic and discoid lupus erythematosus in HIV-infected patients treated with highly active antiretroviral therapy.
    Int J STD AIDS. 2003 May;14(5):356-9 PMID: 12803945
  19. Binding and neutralization activity of human IgG1 and IgG3 from serum of HIV-infected individuals.
    AIDS Res Hum Retroviruses. 2003 Sep;19(9):785-92 PMID: 14585209
  20. A fail-safe mechanism for negative selection of isotype-switched B cell precursors is regulated by the Fas/FasL pathway.
    J Exp Med. 2003 Nov 17;198(10):1609-19 PMID: 14623914
  21. Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide.
    J Infect Dis. 2003 Dec 15;188(12):1827-33 PMID: 14673761
  22. Functional heterogeneity of marginal zone B cells revealed by their ability to generate both early antibody-forming cells and germinal centers with hypermutation and memory in response to a T-dependent antigen.
    J Exp Med. 2003 Dec 15;198(12):1923-35 PMID: 14662910
  23. Inflammation controls B lymphopoiesis by regulating chemokine CXCL12 expression.
    J Exp Med. 2004 Jan 5;199(1):47-58 PMID: 14707114
  24. T cell-independent somatic hypermutation in murine B cells with an immature phenotype.
    Immunity. 2004 Feb;20(2):133-44 PMID: 14975236
  25. HIV vaccine design and the neutralizing antibody problem.
    Nat Immunol. 2004 Mar;5(3):233-6 PMID: 14985706
  26. Regulation of B-cell development by antibody specificity.
    Curr Opin Immunol. 2004 Apr;16(2):246-50 PMID: 15023420
  27. Human immunodeficiency virus infection and systemic lupus erythematosus.
    Int J STD AIDS. 2004 Apr;15(4):277-8 PMID: 15075026
  28. Innate murine B cells produce anti-disialosyl antibodies reactive with Campylobacter jejuni LPS and gangliosides that are polyreactive and encoded by a restricted set of unmutated V genes.
    J Neuroimmunol. 2004 Jul;152(1-2):98-111 PMID: 15223242
  29. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.
    J Virol. 2004 Oct;78(19):10724-37 PMID: 15367639
  30. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10.
    J Immunol. 2004 Oct 1;173(7):4479-91 PMID: 15383579
  31. Autoantibodies, lupus and the science of sabotage.
    Rheumatology (Oxford). 2004 Nov;43(11):1326-36 PMID: 15328419
  32. The scope of receptor editing and its association with autoimmunity.
    Curr Opin Immunol. 2004 Dec;16(6):808-14 PMID: 15511677
  33. Direct polyclonal activation of human B lymphocytes by the acquired immune deficiency syndrome virus.
    Science. 1986 Sep 5;233(4768):1084-6 PMID: 3016902
  34. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes.
    Nature. 1989 Feb 9;337(6207):562-6 PMID: 2783762
  35. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12.
    Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13372-7 PMID: 16174734
  36. Immunoglobulin gene diversification.
    Annu Rev Genet. 2005;39:23-46 PMID: 16285851
  37. What do somatic hypermutation and class switch recombination teach us about chronic lymphocytic leukaemia pathogenesis?
    Curr Top Microbiol Immunol. 2005;294:71-89 PMID: 16323428
  38. CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans.
    Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1166-70 PMID: 11158612
  39. B1 cells: similarities and differences with other B cell subsets.
    Curr Opin Immunol. 2001 Apr;13(2):195-201 PMID: 11228413
  40. Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response.
    Nat Immunol. 2000 Jul;1(1):31-6 PMID: 10881171
  41. Cutting edge: germinal centers can be induced in the absence of T cells.
    J Immunol. 2001 Jul 1;167(1):15-20 PMID: 11418626
  42. Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development.
    J Clin Invest. 2001 Sep;108(6):879-86 PMID: 11560957
  43. A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection.
    Lupus. 1992 Feb;1(2):75-81 PMID: 1301967
  44. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.
    J Virol. 1993 Nov;67(11):6642-7 PMID: 7692082
  45. False-positive human immunodeficiency virus testing in patients with lupus erythematosus.
    Semin Arthritis Rheum. 1993 Aug;23(1):1-7 PMID: 8235661
  46. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.
    Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3348-52 PMID: 7512731
  47. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    J Virol. 1994 Aug;68(8):4821-8 PMID: 7518527
  48. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.
    Science. 1994 Nov 11;266(5187):1024-7 PMID: 7973652
  49. Soluble antigen can cause enhanced apoptosis of germinal-centre B cells.
    Nature. 1995 May 25;375(6529):331-4 PMID: 7753199
  50. Antigen-induced B-cell death and elimination during germinal-centre immune responses.
    Nature. 1995 May 25;375(6529):334-8 PMID: 7753200
  51. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. IV. Affinity-dependent, antigen-driven B cell apoptosis in germinal centers as a mechanism for maintaining self-tolerance.
    J Exp Med. 1995 Dec 1;182(6):1635-44 PMID: 7500008
  52. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.
    J Virol. 1996 Feb;70(2):1100-8 PMID: 8551569
  53. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein.
    J Virol. 1997 Apr;71(4):2674-84 PMID: 9060620
  54. Human immunodeficiency virus infection in systemic lupus erythematosus.
    Arthritis Rheum. 1997 Jun;40(6):1168-72 PMID: 9182929
  55. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
    Nature. 1998 Jun 18;393(6686):648-59 PMID: 9641677
  56. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Nature. 1998 Jun 18;393(6686):705-11 PMID: 9641684
  57. Marginal-zone B cells in the human lymph node and spleen show somatic hypermutations and display clonal expansion.
    Blood. 1999 Jan 1;93(1):226-34 PMID: 9864165
  58. Characterization of IgG monoclonal anti-cardiolipin/anti-beta2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies.
    Br J Haematol. 1999 Apr;105(1):102-9 PMID: 10233371
  59. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals.
    J Exp Med. 1999 Jul 5;190(1):75-89 PMID: 10429672
  60. An IgG antiprothrombin antibody enhances prothrombin binding to damaged endothelial cells and shortens plasma coagulation times.
    Arthritis Rheum. 1999 Oct;42(10):2132-8 PMID: 10524684
  61. Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire.
    Blood. 2004 Dec 1;104(12):3647-54 PMID: 15191950
  62. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
    J Virol. 2005 Jan;79(2):1252-61 PMID: 15613352
  63. Mechanism and control of V(D)J recombination versus class switch recombination: similarities and differences.
    Adv Immunol. 2005;86:43-112 PMID: 15705419
  64. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.
    AIDS Res Hum Retroviruses. 2001 Dec 10;17(18):1757-65 PMID: 11788027
  65. Low-level hypermutation in T cell-independent germinal centers compared with high mutation rates associated with T cell-dependent germinal centers.
    J Exp Med. 2002 Feb 4;195(3):383-9 PMID: 11828014
  66. Temperature differentially affects encounter and docking thermodynamics of antibody--antigen association.
    J Mol Recognit. 2002 Jan-Feb;15(1):44-52 PMID: 11870921
  67. Human immunodeficiency virus infection and systemic lupus erythematosus. An unusual case and a review of the literature.
    Lupus. 2002;11(1):60-3 PMID: 11898923
  68. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.
    J Virol. 2002 Jul;76(14):7306-21 PMID: 12072529
  69. Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barré syndrome.
    Infect Immun. 2002 Sep;70(9):5008-18 PMID: 12183547
Article Info
Journal
Human antibodies
Abbr.
Hum Antibodies
ISSN
1093-2607
Email
hayne002@mc.duke.edu
Published
2005-00-00
Pages
59-67
Language
English
Region
Netherlands
NLM ID
9711270
PMCID
PMC2673565
Subset
IM
Grants
NIAID NIH HHS · U19 AI067854-02 · United States
NIAID NIH HHS · R01 AI087202 · United States
NIAID NIH HHS · P01 AI052816 · United States
NIAID NIH HHS · AI52816 · United States
NIAID NIH HHS · U19 AI067854 · United States
External Links
PubMed source PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2